Polypharmacy, chronic kidney disease, and benign prostatic hyperplasia in patients with chronic obstructive pulmonary disease newly treated with long-acting anticholinergics

•The prevalence of polypharmacy, CKD and, in men, BPH increases with age.•Polypharmacy is highly prevalent across all age in COPD patients initiating a LAAC.•Polypharmacy, CKD, and BPH significantly increase the incidence of AUR.•Physicians should monitor AUR following initiation of a LAAC among COP...

Full description

Saved in:
Bibliographic Details
Published in:Respiratory medicine 2017-11, Vol.132, p.195-202
Main Authors: Savaria, François, Beauchesne, Marie-France, Forget, Amélie, Blais, Lucie
Format: Article
Language:English
Subjects:
Acute urinary retention
Administration, Inhalation
Aged
Anticholinergics
Benign prostatic hyperplasia
Canada - epidemiology
Cholinergic Antagonists - administration & dosage
Cholinergic Antagonists - adverse effects
Chronic kidney disease
Chronic obstructive pulmonary disease
Cohort Studies
Comorbidity
Delayed-Action Preparations - administration & dosage
Delayed-Action Preparations - adverse effects
Drug-Related Side Effects and Adverse Reactions - diagnosis
Genital diseases
Humans
Hyperplasia
Incidence
Kidney diseases
Long-acting anticholinergics
Lung diseases
Male
Middle Aged
Obstructive lung disease
Polypharmacy
Prevalence
Prostatic Hyperplasia - diagnosis
Prostatic Hyperplasia - drug therapy
Prostatic Hyperplasia - epidemiology
Pulmonary Disease, Chronic Obstructive - drug therapy
Pulmonary Disease, Chronic Obstructive - epidemiology
Renal Insufficiency, Chronic - diagnosis
Renal Insufficiency, Chronic - drug therapy
Renal Insufficiency, Chronic - epidemiology
Retrospective Studies
Risk Factors
Urinary Retention - chemically induced
Urinary Retention - diagnosis
Urinary Retention - epidemiology
Urinary Retention - prevention & control
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c428t-e080bf666203f702b8c86c1330aeec66cf31e3b2b475193f3f6379c317dcfeb23
cites cdi_FETCH-LOGICAL-c428t-e080bf666203f702b8c86c1330aeec66cf31e3b2b475193f3f6379c317dcfeb23
container_end_page 202
container_issue
container_start_page 195
container_title Respiratory medicine
container_volume 132
creator Savaria, François
Beauchesne, Marie-France
Forget, Amélie
Blais, Lucie
description •The prevalence of polypharmacy, CKD and, in men, BPH increases with age.•Polypharmacy is highly prevalent across all age in COPD patients initiating a LAAC.•Polypharmacy, CKD, and BPH significantly increase the incidence of AUR.•Physicians should monitor AUR following initiation of a LAAC among COPD patients.
doi_str_mv 10.1016/j.rmed.2017.10.023
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1976006839</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0954611117303621</els_id><sourcerecordid>1983448839</sourcerecordid><originalsourceid>FETCH-LOGICAL-c428t-e080bf666203f702b8c86c1330aeec66cf31e3b2b475193f3f6379c317dcfeb23</originalsourceid><addsrcrecordid>eNp9kc1u1TAQhS0EoreFF2CBLLFh0Vz8k-vEEpuqgoJUCRawthxncuNLYgfbaZWH4h1xlLYLFqwszXznzHgOQm8o2VNCxYfTPozQ7hmhVS7sCePP0I4eOCs4EeVztCPyUBaCUnqGzmM8EUJkWZKX6IxJxiSR1Q79-e6HZep1GLVZLrHpg3fW4F-2dbDg1kbQES6xdi1uwNmjw1PwMemUoX6ZIEyDjlZjmxu5CC5FfG9T_-Tkm5jCbJK9AzzNw-idDk_G2MH9sOAUQCdoN-Hg3bHQWeCOeWye0_vBOghHa-Ir9KLTQ4TXD-8F-vn504_rL8Xtt5uv11e3hSlZnQogNWk6IQQjvKsIa2pTC0M5JxrACGE6ToE3rCmrA5W8453glTScVq3poGH8Ar3ffPNnf88QkxptNDAM2oGfo6KyEoSImsuMvvsHPfk5uLxdpmpelvVGsY0y-XoxQKemYMd8CUWJWsNUJ7WGqdYw11oOM4vePljPzdp7lDyml4GPGwD5FncWgoomR2CgtQFMUq23__P_C-zOtQc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1983448839</pqid></control><display><type>article</type><title>Polypharmacy, chronic kidney disease, and benign prostatic hyperplasia in patients with chronic obstructive pulmonary disease newly treated with long-acting anticholinergics</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>Savaria, François ; Beauchesne, Marie-France ; Forget, Amélie ; Blais, Lucie</creator><creatorcontrib>Savaria, François ; Beauchesne, Marie-France ; Forget, Amélie ; Blais, Lucie</creatorcontrib><description>•The prevalence of polypharmacy, CKD and, in men, BPH increases with age.•Polypharmacy is highly prevalent across all age in COPD patients initiating a LAAC.•Polypharmacy, CKD, and BPH significantly increase the incidence of AUR.•Physicians should monitor AUR following initiation of a LAAC among COPD patients.</description><identifier>ISSN: 0954-6111</identifier><identifier>EISSN: 1532-3064</identifier><identifier>DOI: 10.1016/j.rmed.2017.10.023</identifier><identifier>PMID: 29229097</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Acute urinary retention ; Administration, Inhalation ; Aged ; Anticholinergics ; Benign prostatic hyperplasia ; Canada - epidemiology ; Cholinergic Antagonists - administration &amp; dosage ; Cholinergic Antagonists - adverse effects ; Chronic kidney disease ; Chronic obstructive pulmonary disease ; Cohort Studies ; Comorbidity ; Delayed-Action Preparations - administration &amp; dosage ; Delayed-Action Preparations - adverse effects ; Drug-Related Side Effects and Adverse Reactions - diagnosis ; Genital diseases ; Humans ; Hyperplasia ; Incidence ; Kidney diseases ; Long-acting anticholinergics ; Lung diseases ; Male ; Middle Aged ; Obstructive lung disease ; Polypharmacy ; Prevalence ; Prostatic Hyperplasia - diagnosis ; Prostatic Hyperplasia - drug therapy ; Prostatic Hyperplasia - epidemiology ; Pulmonary Disease, Chronic Obstructive - drug therapy ; Pulmonary Disease, Chronic Obstructive - epidemiology ; Renal Insufficiency, Chronic - diagnosis ; Renal Insufficiency, Chronic - drug therapy ; Renal Insufficiency, Chronic - epidemiology ; Retrospective Studies ; Risk Factors ; Urinary Retention - chemically induced ; Urinary Retention - diagnosis ; Urinary Retention - epidemiology ; Urinary Retention - prevention &amp; control</subject><ispartof>Respiratory medicine, 2017-11, Vol.132, p.195-202</ispartof><rights>2017 Elsevier Ltd</rights><rights>Copyright Elsevier Limited Nov 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c428t-e080bf666203f702b8c86c1330aeec66cf31e3b2b475193f3f6379c317dcfeb23</citedby><cites>FETCH-LOGICAL-c428t-e080bf666203f702b8c86c1330aeec66cf31e3b2b475193f3f6379c317dcfeb23</cites><orcidid>0000-0001-8420-3128</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29229097$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Savaria, François</creatorcontrib><creatorcontrib>Beauchesne, Marie-France</creatorcontrib><creatorcontrib>Forget, Amélie</creatorcontrib><creatorcontrib>Blais, Lucie</creatorcontrib><title>Polypharmacy, chronic kidney disease, and benign prostatic hyperplasia in patients with chronic obstructive pulmonary disease newly treated with long-acting anticholinergics</title><title>Respiratory medicine</title><addtitle>Respir Med</addtitle><description>•The prevalence of polypharmacy, CKD and, in men, BPH increases with age.•Polypharmacy is highly prevalent across all age in COPD patients initiating a LAAC.•Polypharmacy, CKD, and BPH significantly increase the incidence of AUR.•Physicians should monitor AUR following initiation of a LAAC among COPD patients.</description><subject>Acute urinary retention</subject><subject>Administration, Inhalation</subject><subject>Aged</subject><subject>Anticholinergics</subject><subject>Benign prostatic hyperplasia</subject><subject>Canada - epidemiology</subject><subject>Cholinergic Antagonists - administration &amp; dosage</subject><subject>Cholinergic Antagonists - adverse effects</subject><subject>Chronic kidney disease</subject><subject>Chronic obstructive pulmonary disease</subject><subject>Cohort Studies</subject><subject>Comorbidity</subject><subject>Delayed-Action Preparations - administration &amp; dosage</subject><subject>Delayed-Action Preparations - adverse effects</subject><subject>Drug-Related Side Effects and Adverse Reactions - diagnosis</subject><subject>Genital diseases</subject><subject>Humans</subject><subject>Hyperplasia</subject><subject>Incidence</subject><subject>Kidney diseases</subject><subject>Long-acting anticholinergics</subject><subject>Lung diseases</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Obstructive lung disease</subject><subject>Polypharmacy</subject><subject>Prevalence</subject><subject>Prostatic Hyperplasia - diagnosis</subject><subject>Prostatic Hyperplasia - drug therapy</subject><subject>Prostatic Hyperplasia - epidemiology</subject><subject>Pulmonary Disease, Chronic Obstructive - drug therapy</subject><subject>Pulmonary Disease, Chronic Obstructive - epidemiology</subject><subject>Renal Insufficiency, Chronic - diagnosis</subject><subject>Renal Insufficiency, Chronic - drug therapy</subject><subject>Renal Insufficiency, Chronic - epidemiology</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><subject>Urinary Retention - chemically induced</subject><subject>Urinary Retention - diagnosis</subject><subject>Urinary Retention - epidemiology</subject><subject>Urinary Retention - prevention &amp; control</subject><issn>0954-6111</issn><issn>1532-3064</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNp9kc1u1TAQhS0EoreFF2CBLLFh0Vz8k-vEEpuqgoJUCRawthxncuNLYgfbaZWH4h1xlLYLFqwszXznzHgOQm8o2VNCxYfTPozQ7hmhVS7sCePP0I4eOCs4EeVztCPyUBaCUnqGzmM8EUJkWZKX6IxJxiSR1Q79-e6HZep1GLVZLrHpg3fW4F-2dbDg1kbQES6xdi1uwNmjw1PwMemUoX6ZIEyDjlZjmxu5CC5FfG9T_-Tkm5jCbJK9AzzNw-idDk_G2MH9sOAUQCdoN-Hg3bHQWeCOeWye0_vBOghHa-Ir9KLTQ4TXD-8F-vn504_rL8Xtt5uv11e3hSlZnQogNWk6IQQjvKsIa2pTC0M5JxrACGE6ToE3rCmrA5W8453glTScVq3poGH8Ar3ffPNnf88QkxptNDAM2oGfo6KyEoSImsuMvvsHPfk5uLxdpmpelvVGsY0y-XoxQKemYMd8CUWJWsNUJ7WGqdYw11oOM4vePljPzdp7lDyml4GPGwD5FncWgoomR2CgtQFMUq23__P_C-zOtQc</recordid><startdate>201711</startdate><enddate>201711</enddate><creator>Savaria, François</creator><creator>Beauchesne, Marie-France</creator><creator>Forget, Amélie</creator><creator>Blais, Lucie</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U9</scope><scope>ASE</scope><scope>FPQ</scope><scope>H94</scope><scope>K6X</scope><scope>K9.</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-8420-3128</orcidid></search><sort><creationdate>201711</creationdate><title>Polypharmacy, chronic kidney disease, and benign prostatic hyperplasia in patients with chronic obstructive pulmonary disease newly treated with long-acting anticholinergics</title><author>Savaria, François ; Beauchesne, Marie-France ; Forget, Amélie ; Blais, Lucie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c428t-e080bf666203f702b8c86c1330aeec66cf31e3b2b475193f3f6379c317dcfeb23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Acute urinary retention</topic><topic>Administration, Inhalation</topic><topic>Aged</topic><topic>Anticholinergics</topic><topic>Benign prostatic hyperplasia</topic><topic>Canada - epidemiology</topic><topic>Cholinergic Antagonists - administration &amp; dosage</topic><topic>Cholinergic Antagonists - adverse effects</topic><topic>Chronic kidney disease</topic><topic>Chronic obstructive pulmonary disease</topic><topic>Cohort Studies</topic><topic>Comorbidity</topic><topic>Delayed-Action Preparations - administration &amp; dosage</topic><topic>Delayed-Action Preparations - adverse effects</topic><topic>Drug-Related Side Effects and Adverse Reactions - diagnosis</topic><topic>Genital diseases</topic><topic>Humans</topic><topic>Hyperplasia</topic><topic>Incidence</topic><topic>Kidney diseases</topic><topic>Long-acting anticholinergics</topic><topic>Lung diseases</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Obstructive lung disease</topic><topic>Polypharmacy</topic><topic>Prevalence</topic><topic>Prostatic Hyperplasia - diagnosis</topic><topic>Prostatic Hyperplasia - drug therapy</topic><topic>Prostatic Hyperplasia - epidemiology</topic><topic>Pulmonary Disease, Chronic Obstructive - drug therapy</topic><topic>Pulmonary Disease, Chronic Obstructive - epidemiology</topic><topic>Renal Insufficiency, Chronic - diagnosis</topic><topic>Renal Insufficiency, Chronic - drug therapy</topic><topic>Renal Insufficiency, Chronic - epidemiology</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><topic>Urinary Retention - chemically induced</topic><topic>Urinary Retention - diagnosis</topic><topic>Urinary Retention - epidemiology</topic><topic>Urinary Retention - prevention &amp; control</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Savaria, François</creatorcontrib><creatorcontrib>Beauchesne, Marie-France</creatorcontrib><creatorcontrib>Forget, Amélie</creatorcontrib><creatorcontrib>Blais, Lucie</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Virology and AIDS Abstracts</collection><collection>British Nursing Index</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>British Nursing Index</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Respiratory medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Savaria, François</au><au>Beauchesne, Marie-France</au><au>Forget, Amélie</au><au>Blais, Lucie</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Polypharmacy, chronic kidney disease, and benign prostatic hyperplasia in patients with chronic obstructive pulmonary disease newly treated with long-acting anticholinergics</atitle><jtitle>Respiratory medicine</jtitle><addtitle>Respir Med</addtitle><date>2017-11</date><risdate>2017</risdate><volume>132</volume><spage>195</spage><epage>202</epage><pages>195-202</pages><issn>0954-6111</issn><eissn>1532-3064</eissn><abstract>•The prevalence of polypharmacy, CKD and, in men, BPH increases with age.•Polypharmacy is highly prevalent across all age in COPD patients initiating a LAAC.•Polypharmacy, CKD, and BPH significantly increase the incidence of AUR.•Physicians should monitor AUR following initiation of a LAAC among COPD patients.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>29229097</pmid><doi>10.1016/j.rmed.2017.10.023</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0001-8420-3128</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0954-6111
ispartof Respiratory medicine, 2017-11, Vol.132, p.195-202
issn 0954-6111
1532-3064
language eng
recordid cdi_proquest_miscellaneous_1976006839
source ScienceDirect Freedom Collection 2022-2024
subjects Acute urinary retention
Administration, Inhalation
Aged
Anticholinergics
Benign prostatic hyperplasia
Canada - epidemiology
Cholinergic Antagonists - administration & dosage
Cholinergic Antagonists - adverse effects
Chronic kidney disease
Chronic obstructive pulmonary disease
Cohort Studies
Comorbidity
Delayed-Action Preparations - administration & dosage
Delayed-Action Preparations - adverse effects
Drug-Related Side Effects and Adverse Reactions - diagnosis
Genital diseases
Humans
Hyperplasia
Incidence
Kidney diseases
Long-acting anticholinergics
Lung diseases
Male
Middle Aged
Obstructive lung disease
Polypharmacy
Prevalence
Prostatic Hyperplasia - diagnosis
Prostatic Hyperplasia - drug therapy
Prostatic Hyperplasia - epidemiology
Pulmonary Disease, Chronic Obstructive - drug therapy
Pulmonary Disease, Chronic Obstructive - epidemiology
Renal Insufficiency, Chronic - diagnosis
Renal Insufficiency, Chronic - drug therapy
Renal Insufficiency, Chronic - epidemiology
Retrospective Studies
Risk Factors
Urinary Retention - chemically induced
Urinary Retention - diagnosis
Urinary Retention - epidemiology
Urinary Retention - prevention & control
title Polypharmacy, chronic kidney disease, and benign prostatic hyperplasia in patients with chronic obstructive pulmonary disease newly treated with long-acting anticholinergics
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T22%3A28%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Polypharmacy,%20chronic%20kidney%20disease,%20and%20benign%20prostatic%20hyperplasia%20in%20patients%20with%20chronic%20obstructive%20pulmonary%20disease%20newly%20treated%20with%20long-acting%20anticholinergics&rft.jtitle=Respiratory%20medicine&rft.au=Savaria,%20Fran%C3%A7ois&rft.date=2017-11&rft.volume=132&rft.spage=195&rft.epage=202&rft.pages=195-202&rft.issn=0954-6111&rft.eissn=1532-3064&rft_id=info:doi/10.1016/j.rmed.2017.10.023&rft_dat=%3Cproquest_cross%3E1983448839%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c428t-e080bf666203f702b8c86c1330aeec66cf31e3b2b475193f3f6379c317dcfeb23%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1983448839&rft_id=info:pmid/29229097&rfr_iscdi=true